Subchronic toxicity and toxicogenomic evaluation of Tamoxifen citrate + Bexarotene in female rats

Toxicological Sciences

Volumn 99, Issue 2, 2007, Pages 612-627

  Horn, Thomas L ^a   Torres, Karen E O ^a   Naylor, Jennifer M ^a   Cwik, Michael J ^a   Detrisac, Carol J ^b   Kapetanovic, Izet M ^c   Lubet, Ronald A ^c   Crowell, James A ^c   Mccormick, David L ^a  

^a IIT RESEARCH INSTITUTE   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bexarotene; Chemoprevention; Preclinical toxicity; Rat; Tamoxifen; Toxicogenomics

Indexed keywords

ADIPSIN; ALPHA1 GLYCOPROTEIN; APROTININ; BEXAROTENE; CALCIUM CHANNEL; CARBOXYPEPTIDASE A; CARBOXYPEPTIDASE A 1; CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE 1 B; CHEMOKINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYTOCHROME A1; CYTOCHROME P450 17; CYTOCHROME P450 2A1; EARLY GROWTH RESPONSE FACTOR 1; FATTY ACID SYNTHASE; FICOLIN; FICOLIN A; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; LEUKEMIA INHIBITORY FACTOR RECEPTOR; LONG CHAIN FATTY ACID COENZYME A LIGASE; MANNOSE RECEPTOR; NUCLEAR PROTEIN; NUCLEAR PROTEIN 3; PROLACTIN RECEPTOR; SERINE PROTEINASE INHIBITOR; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; TAMOXIFEN CITRATE; UNINDEXED DRUG; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; TAMOXIFEN; TETRALIN DERIVATIVE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CHRONIC TOXICITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG METABOLISM; EPIDERMIS HYPERPLASIA; FATTY ACID METABOLISM; FEMALE; GENE EXPRESSION; HUMAN; HYPERKERATOSIS; HYPERTROPHY; LIPID METABOLISM; LIVER HISTOLOGY; MONOTHERAPY; MUCOUS CELL HYPERTROPHY; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; STEROID METABOLISM; THROMBOCYTOPENIA; TOXICOGENETICS; TRIACYLGLYCEROL BLOOD LEVEL; UNINDEXED SEQUENCE; UTERINE CERVIX MUCUS; VAGINA; VAGINA MUCUS; ANIMAL; BLOOD; CHEMISTRY; DIMERIZATION; DNA MICROARRAY; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION PROFILING; LIVER; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT;

RATTUS; RODENTIA;

ANIMALS; DIMERIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION PROFILING; LIVER; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PPAR ALPHA; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAMOXIFEN; TETRAHYDRONAPHTHALENES; TOXICOGENETICS;

EID: 38449119846     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfm181     Document Type: Article

References (40)

1. Anzano, M. A., Byers, S. W., Smith, J. M., Peer, C. W., Mullen, L. T., Brown, C. C., Roberts, A. B., and Sporn, M. B. (1994). Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res. 54, 4614-4617.
2. Anzano, M. A., Peer, C. W., Smith, J. M., Mullen, L. T., Shrader, M. W., Logsdon, D. L., Driver, C. L., Brown, C. C., Roberts, A. B., and Sporn, M. B. (1996). Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid. J. Natl. Cancer Inst. 88, 123-125.
3. Bischoff, E. D., Gottardis, M. M., Moon, T. E., Heyman, R. A., and Lamph, W. W. (1998). Beyond tamoxifen: The retinoid X receptor-selective ligand LGD1069 (Targretin) causes complete regression of mammary carcinoma. Cancer Res. 58, 479-484.
4. Bischoff, E. D., Heyman, R. A., and Lamph, W. W. (1999). Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure. J. Natl. Cancer Inst. 91, 2118-2123.
5. Cariello, N. F., Romach, E. H., Colton, H. M., Ni, H., Yoon, L., Falls, J. G., Casey, W., Creech, D., Anderson, S. P., Benavides, G. R., et al. (2005). Gene expression profiling of the PPAR-alpha agonist ciprofibrate in the cynomolgus monkey liver. Toxicol. Sci. 88 250-264.
6. Carthew, P., Edwards, R. E., Nolan, B. M., Martin, E. A., and Smith, L. L. (1996). Tamoxifen associated uterine pathology in rodents: Relevance to women. Carcinogenesis 17, 1577-1582.
7. Dragan, Y. P., Fahey, S., Nuwaysir, E., Sattler, C., Babcock, K., Vaughan, J., McCague, R., Jordan, V. C., and Pitot, H. C. (1996). The effect of tamoxifen and two of its non-isomerizable fixed-ring analogs on multistage rat hepato-carcinogenesis. Carcinogenesis 17, 585-594.
8. Duvic, M., Martin, A. G., Kim, Y., Olsen, E., Wood, G. S., Crowley, C. A., and Yocum, R. C. for the Worldwide Bexarotene Study Group (2001). Phase 2 and 3 clinical trial of oral Bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch. Dermatol. 137, 581-593.
9. Esteva, F. J., Glaspy, J., Baidas, S., Laufman, L., Hutchins, L., Dickler, M., Tripathy, D., Cohen, R., DeMichele, A., Yocum, R. C., et al. (2003). Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J. Clin. Oncol. 21, 999-1006.
10. Farol, L. T., and Hymes, K. B. (2004). Bexarotene: A clinical review. Expert Rev. Anticancer Ther. 4, 180-188.
11. Fisher, B., Costantino, J. P., Wickerham, D. L., Cecchini, R. S., Cronin, W. M., Robidoux, A., Bevers, T. B., Kavanah, M. T., Atkins, J. N., Margolese, R. G., et al. (2005). Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst. 97 1652-1662.
12. Germain, P., Chambon, P., Eichele, G., Evans, R. M., Lazar, M. A., Leid, M., De Lera, A. R., Lotan, R., Mangelsdorf, D. J., and Gronemeyer, H. (2006). International Union of Pharmacology. LXIII. Retinoid X Receptors. Pharmacol. Rev. 58, 760-772.
13. Gottardis, M. M., Bischoff, E. D., Shirley, M. A., Wagoner, M. A., Lamph, W. W., and Heyman, R. A. (1996). Chemoprevention of mammary carcinoma by LGD1069 (Targretin): An RXR-selective ligand. Cancer Res. 56, 5566-5570.
14. Heald, P., Mehlmauer, M., Martin, A. G., Crowley, C. A., Yocum, R. C., and Reich, S. D. (2003). Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: Results of the phase III clinical trial. J. Am. Acad. Dermatol. 49, 801-815.
15. IJpenberg, A., Nguan, S. T., Gelman, L., Kersten, S., Seydoux, J., Xu, J., Metzger, D., Canaple, L., Chambon, P., Wahli, W., et al. (2004). In vivo activation of PPARtarget genes by RXRhomodimers. EMBO J. 23, 2083-2091.
16. Kang, H. W., Bhimidi, G. R., Odom, D. P., Brun, P.-J., Fernandez, M.-L., and McGrane, M. M. (2007). Altered lipid catabolism in the vitamin A deficient liver. Mol. Cell. Endocrinol. 271, 18-27.
17. Kennel, P., Pallen, C., Barale-Thomas, E., Espuña, G., and Bars, R. (2003). Tamoxifen: 28-day oral toxicity study in the rat based on the Enhanced Test Guideline 407 to detect endocrine effects. Arch. Toxicol. 77, 487-499.
18. Lalloyer, F., Fiévet, C., Lestavel, S., Torpier, G., van der Veen, J., Touche, V., Bultel, S., Yous, S., Kuipers, F., Paumelle, R., et al. (2006). The RXR agonist bexarotene improves cholesterol homeostasis and inhibits athero-sclerosis progression in a mouse model of mixed dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 26, 2731-2737.
19. Lowe, M. N., and Plosker, G. L. (2000). Bexarotene. Am. J. Clin. Dermatol. 1, 245-250.
20. Lubet, R. A., Christov, K., Nunez, N. P., Hursting, S. D., Steele, V. E., Juliana, M. M., Eto, I., and Grubbs, C. J. (2005). Efficacy of Targretin on methylnitrosourea-induced mammary cancers: Prevention and therapy dose-response curves and effects on proliferation and apoptosis. Carcinogenesis 26, 441-448.
21. McCormick, D. L., and Moon, R. C. (1986). Retinoid-tamoxifen interaction in mammary cancer chemoprevention. Carcinogenesis 7, 193-196.
22. McCormick, D. L., Johnson, W. D., Bosland, M. C., Lubet, R. A., and Steele, V. E. (2007). Target identification for prostate cancer chemoprevention: Differential anticarcinogenic activity of RAR and RXR agonists in the Wistar-Unilever rat. Proc. Am. Assoc. Cancer Res. 48, 1665 (Abstract).
23. McCormick, D. L., Rao, K. V. N., Steele, V. E., Lubet, R. A., Kelloff, G. J., and Bosland, M. C. (1999). Chemoprevention of rat prostate carcinogenesis by 9-cis-retinoic acid. Cancer Res. 59, 521-524.
24. Michalik, L., Auwerx, J., Berger, J. P., Chatterjee, V. K., Glass, C. K., Gonzalez, F. J., Grimaldi, P. A., Kadowaki, T., Lazar, M. A., O'Rahilly, S., et al. (2006). International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 58 726-741.
25. Nayfield, S. G. (1995). Tamoxifen's role in chemoprevention of breast cancer: An update. J. Cell. Biochem. (Suppl.), 22, 42-50.
26. Osborne, C. K., Jarman, M., McCague, R., Coronado, E. B., Hilsenbeck, S. G., and Wakeling, A. E. (1994). The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother. Pharmacol. 34, 89-95.
27. Ouamrane, L., Larrieu, G., Gauthier, B., and Pineau, T. (2003). RXR activators molecular signaling: Involvement of a PPARα-dependent pathway in the liver and kidney, evidence for an alternative pathway in the heart. Br. J. Pharmacol. 138, 845-854.
28. Penniston, K. L., and Tanumihardio, S. A. (2006). The acute and chronic toxic effects of vitamin A. Am. J. Clin. Nutr. 83, 191-201.
29. Querfeld, C., Rosen, S. T., Guitart, J., Rademaker, A., Fung, B. B., Posten, W., and Kuzel, T. M. (2004). Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 51, 25-32.
30. Silverman, A. K., Ellis, C. N., and Voorhees, J. J. (1987). Hypervitaminosis A syndrome: A paradigm of retinoid side effects. J. Am. Acad. Dermatol. 16, 1027-1039.
31. Suh, N., Lamph, W. W., Glasebrook, A. L., Grese, T. A., Palkowitz, A. D., Williams, C. R., Risingsong, R., Farris, M. R., Heyman, R. A., and Sporn, M. B. (2002). Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. Clin. Cancer Res. 8, 3270-3275.
32. Wade, G. N., and Heller, H. W. (1993). Tamoxifen mimics the effects of estradiol on food intake, body weight, and body composition in rats. Am. J. Physiol. 264, R1219-R1223.
33. Wakeling, A. E. (1995). Tissue-specific actions of antioestrogens. Mutat. Res. 333, 45-49.
34. Wallen, W. J., Belanger, M. P., and Wittnich, C. (2001). Sex hormones and the selective estrogen receptor modulator tamoxifen modulate weekly body weights and food intakes in adolescent and adult rats. J. Nutr. 131, 2351-2357.
35. Wallen, W. J., Belanger, M. P., and Wittnich, C. (2002). Body weight and food intake profiles are modulated by sex hormones and tamoxifen in chronically hypertensive rats. J. Nutr. 132, 2246-2250.
36. Wan, Y.-J. Y., An, D., Cai, Y., Repa, J. J., Chen, T. H.-P., Flores, M., Postic, C., Magnuson, M. A., Chen, J., Chien, K. R., et al. (2000). Hepatocyte-specific mutation establishes retinoid X receptor α as a heterodimeric integrator of multiple physiologic processes in the liver. Mol. Cell. Biol. 20, 4436-4444.
37. Wu, K., Kim, H.-T., Rodriquez, J. L., Hilsenbeck, S. G., Mohsin, S. K., Xu, X.-C., Lamph, W. W., Kuhn, J. G., Green, J. E., and Brown, P. H. (2002a). Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol. Biomarkers Prev. 11, 467-474.
38. Wu, K., Zhang, Y., Xu, X.-C., Hill, J., Celestino, J., Kim, H.-T., Mohsin, S. K., Hilsenbeck, S. G., Lamph, W. W., Bissonette, R., et al. (2002b). The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res. 62, 6376-6380.
39. Yen, W.-C., and Lamph, W. W. (2005). The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma. Mol. Cancer Ther. 4 824-834.
40. Yen, W.-C., Prudente, R. Y., and Lamph, W. W. (2004). Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma. Breast Cancer Res. Treat. 88, 141-148.